MRUS Jan 2025 60.000 call
OPR - OPR Delayed price. Currency in USD
Add to watchlist
As of 09:30AM EDT. Market open.
| Previous close | 6.60 |
| Open | 6.60 |
| Bid | 3.90 |
| Ask | 8.30 |
| Strike | 60.00 |
| Expiry date | 2025-01-17 |
| Day's range | 6.60 - 6.60 |
| Contract range | N/A |
| Volume | |
| Open interest | 49 |
GlobeNewswirePetosemtamab granted Breakthrough Therapy Designation by the U.S. FDA
Petosemtamab granted BTD for the treatment of previously treated HNSCC UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®) for cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for petosemtamab for the treatment of patients with recurrent or metast
Simply Wall St.Merus N.V. (NASDAQ:MRUS) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates
Merus N.V. ( NASDAQ:MRUS ) shareholders are probably feeling a little disappointed, since its shares fell 7.9% to...
- Simply Wall St.
Investors push Merus (NASDAQ:MRUS) 5.0% lower this week, company's increasing losses might be to blame
When you buy a stock there is always a possibility that it could drop 100%. But on the bright side, you can make far...
© 2024 Yahoo. All rights reserved.